Our goal with LIFE-L is to show that lifestyle interventions aren’t just for prevention or post-treatment—they can make a real difference during treatment. If we can help patients feel stronger and ...
The fossilized remains of a very unlucky bird that lived about 120 million years ago reveal something that's rarely clear ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...
The novel spectroscopy setup, pictured here, used to detect the extremely faint, long-timescale signals emitted by ...
Treatment with intravenous (IV) iron significantly improved survival and increased hemoglobin levels in patients with iron-deficiency anemia who were hospitalized for an acute bacterial infection, ...
Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s ...
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term ...
A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...
ACCESS study reveals patients can safely receive stem cell transplants from unrelated donors with multiple genetic mismatches. A protective regimen acts as a “bridge,” preventing complications and ...
EMBARGOED: A new study to be presented Dec. 6 at the 2025 American Society of Hematology (ASH) meeting reveals that even subtle disruptions in genome architecture can predispose individuals to ...
The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback